Amgen's earnings call details a strong 2012 performance underpinned by significant product sales growth, strategic acquisitions, and robust cash returns to shareholders. The company projected steady revenue and EPS growth for 2013, with well-managed debt levels and cash reserves supporting continuous investment in its pipeline and expanding operations. Despite potential challenges from competition and macroeconomic pressures, Amgen's strategic focus and strong financial health suggest positive investor sentiment for the short term.

[1]